



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)

Date: July 9, 2020

Time: 10:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neurosciences Center Building
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Boulevard, Room 4242, MSC 9550
Bethesda, MD 20892
(301) 827-5833
ivan.navarro@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel R13
Conference Grant Review

Date: July 10, 2020

Time: 1:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neurosciences Center Building
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Boulevard
Room 4235 MSC 9550
Bethesda, MD 20892-9550
(301) 827-5819
gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Device-Based
Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional)

Date: July 10, 2020

Time: 1:00 PM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neurosciences Center Building
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Boulevard, Room 4242, MSC 9550
Bethesda, MD 20892
(301) 827-5833
ivan.navarro@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required)

Date: July 15, 2020

Time: 12:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neurosciences Center Building
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Sheila Pirooznia, Ph.D.
Scientific Review Officer
Scientific Review Branch
Division of Extramural Review
National Institute on Drug Abuse
6001 Executive Blvd
Bethesda, MD 20892
(301) 496-9350
sheila.pirooznia@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: June 3, 2020.

Tyeshia M. Roberson,
Program Analyst,
Office of Federal Advisory Committee Policy.
[FR Doc. 2020-12368 Filed: 6/8/2020 8:45 am; Publication Date: 6/9/2020]